1.
Am J Gastroenterol
; 114(7): 1172-1175, 2019 07.
Artículo
en Inglés
| MEDLINE
| ID: mdl-30920987
RESUMEN
OBJECTIVES: Despite encouraging data gathered in inflammatory bowel diseases (IBD) patients, Vedolizumabs' (VDZ) safety profile in pregnancy is not established. DESIGN: Data of 330 consecutive pregnancies with IBD was prospectively collected. RESULTS: Women with IBD were treated with: VDZ (n = 24), anti-tumor necrosis factors (n = 82) or conventional therapy (n = 224). Gravidity and parity were similar among the 3 groups. The VDZ group was comprised mostly of Crohn's disease patients who were all not naïve to biological treatment. They had significantly higher conception rates during active disease (P < 0.05), with fewer flares during pregnancy. DISCUSSION: Although further study is needed, VDZ appears of low risk during pregnancy.
Asunto(s)
Anticuerpos Monoclonales Humanizados/uso terapéutico , Enfermedades Inflamatorias del Intestino/tratamiento farmacológico , Seguridad del Paciente , Resultado del Embarazo , Factor de Necrosis Tumoral alfa/uso terapéutico , Adulto , Anticuerpos Monoclonales Humanizados/efectos adversos , Estudios de Cohortes , Enfermedad de Crohn/diagnóstico , Enfermedad de Crohn/tratamiento farmacológico , Femenino , Fármacos Gastrointestinales/administración & dosificación , Fármacos Gastrointestinales/efectos adversos , Humanos , Recién Nacido , Enfermedades Inflamatorias del Intestino/diagnóstico , Embarazo , Embarazo de Alto Riesgo , Pronóstico , Estudios Prospectivos , Medición de Riesgo
2.
Inflamm Bowel Dis
; 27(5): 742-745, 2021 04 15.
Artículo
en Inglés
| MEDLINE
| ID: mdl-33386732